1992. Is there the will for there to be a way?

Area of Science:

• Pharmaceutical regulatory affairs
• European market integration
• Drug registration policies

Background:

• The European Community aimed for a fully integrated market by 1992.
• Divergent national pharmaceutical registration requirements hindered market integration.
• A non-mandatory mutual recognition process failed to resolve these barriers.

Purpose of the Study:

• To recommend measures for abolishing remaining barriers in pharmaceutical product registration.
• To achieve a single authorization for simultaneous approvals across all member states.
• To address the lack of consensus on regulatory harmonization.

Main Methods:

• Analysis of existing regulatory frameworks and barriers.
• Review of proposed solutions including mandatory mutual recognition and a central agency.
• Development of a tripartite solution balancing national and central responsibilities.

Main Results:

• No clear consensus exists on the optimal approach for pharmaceutical registration harmonization.
• Recommendations include mandatory mutual recognition, a central European Agency, or a combination.
• A tripartite solution is proposed, sharing responsibilities between National Agencies and a central European body.

Conclusions:

• A tripartite model is recommended for European pharmaceutical registration.
• This model involves a European Secretariat for coordination and appeals, and National Agencies for assessments.
• The Committee for Proprietary Medicinal Products (CPMP) would oversee personnel education standards.